Newsroom

BOSTON & WARSAW, Poland & COLOGNE, Germany--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance Announces Entry Into Poland, and Carsten Keune as Country Manager...

BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced the company will present promising preliminary clinical data from the ongoing Phase 1 portion of its Phase 1/2 PROSPER trial evaluating FMC-376, an equipotent KRAS G12C ON+OFF inhibitor, in patients with advanced KRA...

NORWALK, Conn. & AMSTERDAM & NEW YORK--(BUSINESS WIRE)--Silgan Holdings Inc. (NYSE: SLGN) (“Silgan” or the “Company”), Trivium Packaging B.V. (“Trivium”), and funds affiliated with American Industrial Partners ("AIP") today announced a proposed transaction that will combine Silgan's Metal Containers segment and Food and Beverage Flat Cap Closures businesses with Trivium to create Silgan Metal Containers and Closures (“Silgan MCC”). The combination is a transformational next step that accelerate...

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations or other uncommon EGFR mutations and active central nervous system (CNS) metastases. The data will be...

WOBURN, Mass.--(BUSINESS WIRE)--SES AI Corporation (“SES AI,” the “Company,” “we” or “us”) (NYSE: SES), a global leader in the development and manufacturing of AI-enhanced high-performance Li-Metal and Li-ion batteries, today announced that it has completed the ramp up of its drone battery plant in Chungju, Korea, to an annual production capacity of one million NDAA-compliant cells. Driven by stronger than expected customer demand, the Company plans to immediately begin expanding the plant furt...

NEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)--TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq: TCGX), a special purpose acquisition company (SPAC) sponsored by TCGX, today announced the execution of a definitive business combination agreement that will result in TriGemX Bio becoming a publicly traded company. The combined company will be named “TriGemX Bio, Inc.” (the “Combined Company”...

NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--monday.com (NASDAQ: MNDY) today announced it will report its financial results for the third quarter of 2026 on Monday, November 9, 2026. monday.com management will host a conference call and webcast to discuss the results that morning at 8:30 a.m. Eastern Time.Information about monday.com’s financial results, including a link to the live webcast of the conference call, will be made available on monday.com’s investor relations website at https://ir.m...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company’s investigational new drug application to proceed with the SUMMIT clinical trial of treprostinil SMI in PH-COPD. The phase 2, 16-week, double blind SUMMIT study will evaluate the safety and tolerability of treprostinil SMI in approximately 40 patie...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - February 16.10.2026 GFEB.LN IE000X8M8M80  650,002.00 USD  26,150,147.86   40.231  ...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in previously untreated advanced clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. The study (SMT112-216 / AK112-216 / NCT07877194) is being conducted in collaboration with Summit’s partner, Akeso Inc. SMT...